Pair Name	Myriocin, Cisplatin
Disease Info	[ICD-11: 2C30]	Melanoma		Investigative
Biological Phenomena	Inhibition-->Angiogenesis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Down-regulation	Phosphorylation	KDR	hsa3791
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Phosphorylation	NFKBIA	hsa4792
	Down-regulation	Phosphorylation	NOS3	hsa4846
	Down-regulation	Phosphorylation	PIK3CA	hsa5290
	Down-regulation	Phosphorylation	PTK2	hsa5747
	Down-regulation	Phosphorylation	RELA	hsa5970
In Vitro Model	3LL	Malignant tumors of the mouse pulmonary system	Mus musculus (Mouse)	CVCL_5653
	B16-F10	Mouse melanoma	Mus musculus (Mouse)	CVCL_0159
	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	HUVEC-C	Healthy	Homo sapiens (Human)	CVCL_2959
	EA.hy 926	Healthy	Homo sapiens (Human)	CVCL_3901
In Vivo Model	B16F10 or LLC cells (5×10⁵ cells in 200 μl) were subcutaneously (s.c.) injected into the flanks of 5–6 weeks-old C57BL/6 J male mice.
Result	We suggest that myriocin is a novel potent anti-cancer agent that dually targets both VEGFR2 in ECs and IκBα in cancer cells, and exerts more pronounced anti-tumor effects than with either kinase being inhibited alone.